http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
-
Amgen To Webcast Investor Call At ASH 2018
-
Amgen To Present At the Piper Jaffray And Evercore ISI Healthcare Conferences
-
Amgen (AMGN) Receives CHMP Positive Opinion To Expand Use Of BLINCYTO In Patients With Minimal Residual Disease-Positive B-Cell Precursor ALL
-
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
-
Amgen (AMGN) Highlights Long-Term Safety & Efficacy Results for Repatha (Evolocumab) in Longest Duration Study of a PCSK9 Inhibitor
-
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
-
Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
-
Amgen Announces Presentation Of Research Reinforcing The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In High-Risk Patients At AHA Scientific Sessions 2018
-
Amgen (AMGN), Provention Bio (PRVB) Announce Co-Development Collaboration In Celiac Disease
-
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
-
Amgen To Present New Data Showcasing Extensive Portfolio And Exciting Early Oncology Pipeline At ASH 2018
-
Amgen Foundation Deepens Commitment To Aspiring Scientists Worldwide By Expanding Amgen Scholars Program
-
From pharma to prisons, election-sensitive stocks that could swing
-
Amgen Reports Third Quarter 2018 Financial Results
-
Amgen Announces New FOURIER Analysis Showing Benefit With Repatha® (Evolocumab) In High-Risk Patients With Established Cardiovascular Disease And Chronic Kidney Disease
-
Amgen Announces Webcast Of 2018 Third Quarter Financial Results
-
Amgen (AMGN) Makes Repatha Available in the US At 60% Reduced List Price
-
Amgen Makes Repatha® (Evolocumab) Available In The US At A 60 Percent Reduced List Price
-
Amgen (AMGN) Says Trial of TNF Inhibitor Versus Methotrexate Monotherapy in PsA Shows ENBREL Monotherapy and Combination Therapy Both Superior to Methotrexate
-
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
-
Amgen Announces 2018 Fourth Quarter Dividend
-
Amgen (AMGN) Announces $66M Equity Investment in Oxford Nanopore Technologies
-
Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies
-
Express Scripts (ESRX) Announces New Value-Based Program for Migraine
-
Amgen (AMGN) Announces Launch of AMGEVITA (Biosimilar Adalimumab) Across Europe
-
Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
-
Amgen (AMGN) Says FDA Approved KYPROLIS Once-Weekly 70 mg/m2 In Combination With Dexamethasone For Patients With R/R Multiple Myeloma
-
FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
-
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
-
Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA
-
World's Largest Alzheimer's Survey Reveals Most Adults Believe a Cure Will be Developed in Their Lifetime
-
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
-
Amgen To Present At The Morgan Stanley Global Healthcare Conference
-
Tezepelumab Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Severe Asthma Without An Eosinophilic Phenotype
-
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
-
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS
-
Amgen And LabCentral Open Nomination Process For Lab Residency
-
Amgen (AMGN) Says EC Approves BLINCYTO For Use In Pediatric Patients With Philadelphia Chromosome-Negative R/R B-Cell Precursor ALL
-
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
-
Amgen (AMGN) Submits Supplemental NDA For KYPROLIS Once-Weekly 70 mg/m2 In Combination With Dexamethasone
-
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
-
Amgen To Present Robust Data Exploring The Impact Of Treatment With Repatha® (evolocumab) Across Patient Subgroups And High-Risk Populations At ESC Congress 2018
-
Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
-
Amgen Announces 2018 Third Quarter Dividend
-
Amgen Announces Succession Plans For Two Executive Officers
-
Amgen Reports Second Quarter 2018 Financial Results
-
Amgen Announces Webcast of 2018 Second Quarter Financial Results
-
Pfizer (PFE) Announces FDA Approves for its Neupogen Biosimilar NIVESTYM
-
Amgen And Cedars-Sinai Partner For Improved Healthcare Quality

